July 26th 2024
FDA’s Oncologic Drugs Advisory Committee acknowledged that Imfinzi met its primary endpoint of event-free survival in the treatment of resectable non-small cell lung cancer.
Now more than two years into launching his alternative and transparent drug payment model, the longtime entrepreneur discusses the prescription drug cost landscape and shares his recipe for true disruption to the pharma pricing machine.
Addressing OUD Treatment Gaps & Improving Patient Outcomes
July 23rd 2024In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses how the findings from this study contribute to addressing treatment gaps and improving patient outcomes for those struggling with fentanyl dependence, ensuring broader patient access to BRIXADI®, and more.
Braeburn on BRIXADI® Research and Addressing Fentanyl's Impact on OUD
July 22nd 2024In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses data from the Phase III trial recently published in JAMA and how confident they are in the generalizability of these findings to a real-world treatment setting.